Literature DB >> 20224312

Clinical predictors and risk factors for relapsing Clostridium difficile infection.

Jose Cadena1, George R Thompson, Jan E Patterson, Brandy Nakashima, Aaron Owens, Kelly Echevarria, Eric M Mortensen.   

Abstract

BACKGROUND: Clostridium difficile infection (CDI) is a common cause of morbidity among hospitalized patients. Multiple factors have been associated with primary CDI, but risk factors for CDI relapses are less well described.
METHODS: This was a retrospective cohort study of patients with CDI over a 15-month period. We compared patients with relapsing and nonrelapsing CDI, including risk factors associated with primary CDI and other variables hypothesized to be associated with relapsing CDI and 90-day mortality. Multivariable logistic regression models were created to examine risk factors for relapse and 90-day mortality.
RESULTS: One hundred twenty-nine consecutive patients with CDI were included; 38 (29%) had relapsing CDI. Factors associated with relapsing CDI included fluoroquinolone use (71% versus 49%, P = 0.04) and incidence of stroke (29% versus 12%, P = 0.02). In a regression model, use of a fluoroquinolone was associated with relapsing CDI (OR = 2.52, 95% CI = 1.11-5.72). Factors associated with 90-day mortality included higher Charlson comorbidity index score (4.34 +/- 1.71 versus 3.42 +/- 2.08, P = 0.02), severe CDI (58% versus 32%, P = 0.01), and the use of piperacillin/tazobactam (45% versus 23%, P = 0.03) or meropenem (10% versus 1%, P = 0.04). In the regression analysis, 90-day mortality was associated with severe CDI (OR = 1.76; 95% CI = 1.19-2.59).
CONCLUSION: Fluoroquinolone use and prior stroke are associated with an increased risk of relapsing CDI. Relapsing CDI and severe CDI are both associated with increased 90-day mortality.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20224312     DOI: 10.1097/MAJ.0b013e3181d3cdaa

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  17 in total

Review 1.  Recurrent Clostridium difficile infection and the microbiome.

Authors:  Rowena Almeida; Teklu Gerbaba; Elaine O Petrof
Journal:  J Gastroenterol       Date:  2015-07-08       Impact factor: 7.527

Review 2.  Treatment of refractory and recurrent Clostridium difficile infection.

Authors:  Christina M Surawicz; Jacob Alexander
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-04-19       Impact factor: 46.802

Review 3.  Recurrent Clostridium difficile infection: what are the treatment options?

Authors:  Claire M F van Nispen tot Pannerden; Annelies Verbon; Ernst J Kuipers
Journal:  Drugs       Date:  2011-05-07       Impact factor: 9.546

4.  First recurrence of Clostridium difficile infection: clinical relevance, risk factors, and prognosis.

Authors:  T Larrainzar-Coghen; D Rodriguez-Pardo; M Puig-Asensio; V Rodríguez; C Ferrer; R Bartolomé; C Pigrau; N Fernández-Hidalgo; T Pumarola; B Almirante
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-01-11       Impact factor: 3.267

Review 5.  Association of Gastric Acid Suppression With Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis.

Authors:  Raseen Tariq; Siddharth Singh; Arjun Gupta; Darrell S Pardi; Sahil Khanna
Journal:  JAMA Intern Med       Date:  2017-06-01       Impact factor: 21.873

6.  Risk factors for recurrent Clostridium difficile infection in a tertiary hospital in Israel.

Authors:  Wasef Na'amnih; Amos Adler; Tamar Miller-Roll; Dani Cohen; Yehuda Carmeli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-04-07       Impact factor: 3.267

7.  Risk factors for recurrent Clostridium difficile infection in allogeneic hematopoietic cell transplant recipients.

Authors:  S Mani; L Rybicki; D Jagadeesh; S B Mossad
Journal:  Bone Marrow Transplant       Date:  2016-01-04       Impact factor: 5.483

8.  Clostridium difficile ribotype does not predict severe infection.

Authors:  Seth T Walk; Dejan Micic; Ruchika Jain; Eugene S Lo; Itishree Trivedi; Eugene W Liu; Luay M Almassalha; Sarah A Ewing; Cathrin Ring; Andrzej T Galecki; Mary A M Rogers; Laraine Washer; Duane W Newton; Preeti N Malani; Vincent B Young; David M Aronoff
Journal:  Clin Infect Dis       Date:  2012-09-12       Impact factor: 9.079

9.  The efficacy of fidaxomicin in the treatment of Clostridium difficile infection in a real-world clinical setting: a Spanish multi-centre retrospective cohort.

Authors:  C Fehér; E Múñez Rubio; P Merino Amador; A Delgado-Iribarren Garcia-Campero; M Salavert; E Merino; E Maseda Garrido; V Díaz-Brito; M J Álvarez; J Mensa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-10-08       Impact factor: 3.267

10.  Probiotics for Clostridium difficile infection in adults (PICO): Study protocol for a double-blind, randomized controlled trial.

Authors:  Anna Barker; Megan Duster; Susan Valentine; Laurie Archbald-Pannone; Richard Guerrant; Nasia Safdar
Journal:  Contemp Clin Trials       Date:  2015-07-22       Impact factor: 2.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.